Blackstone Life Sciences
-
Blackstone Life Sciences Commits Up To $300 Million to Malvern-Based Uniquity Bio
Malvern-based Uniquity Bio is emerging from stealth mode after getting up to $300 million from Massachusetts-based private equity firm Blackstone Life Sciences, writes John George…
-
Malvern’s Galera Therapeutics in Line for $37.5 Million Payday
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on the new drug…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
